A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
The purpose of this study is to evaluate, in participants having achieved a state of sustained remission, if the ixekizumab treatment groups are superior to the placebo group in maintaining response during the randomized withdrawal-retreatment period in participants with axial spondyloarthritis.
Inclusion Criteria:
(Note: Participants from Study RHBX are not eligible if they permanently discontinued ixekizumab and were receiving a tumor necrosis factor [TNF] inhibitor).
Exclusion Criteria:
Colorado Springs, Colorado 80920, United States
Columbia, South Carolina 29204, United States
Summerville, South Carolina 29486, United States
Ciudad de Buenos Aires, Buenos Aires C1430EGF, Argentina
Ciudad Autonoma de Buenos Aire, C1428DZF, Argentina
Rio de Janeiro, Rio de Janeiro 22271-100, Brazil
Kita-gun, Kagawa-ken 761-0793, Japan
Suita-shi, Osaka 565 0871, Japan
Bunkyo-ku, Tokyo 113-8431, Japan
Chuo-Ku, Tokyo 104 8560, Japan
San Luis PotosĆ City, San Luis PotosĆ 78213, Mexico
Songpa-gu, Seoul 05505, South Korea